ClinicalTrials.gg
CompletedNCT04507269Updated Aug 26, 2024Results posted

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

A Phase 2 interventional study of VIR-2218 and Placebo in Hepatitis B, Chronic, sponsored by Brii Biosciences Limited. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
255th of 273
21 · median 120
Started
2020
with 28 others
Phase 2
72 of 375
15 open now
Registered
198th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 255th largest by enrollment of the 273 interventional ones that give a count, is one of 29 that started in 2020, is one of 72 in phase 2, and was the 198th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.

03

Conditions studied

  • Hepatitis B, Chronic

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18 - 65;
  • Weight ≥ 40 kg to ≤ 125 kg;
  • Chronic infection as defined by a positive serum HBsAg for ≥ 6 months;

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the volunteer unsuitable for participation;
  • Significant fibrosis or cirrhosis;
  • History or evidence of drug or alcohol abuse;
  • History of intolerance to SC injection;
  • History of chronic liver disease from any cause other than chronic infection;
  • History of hepatic decompensation;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    VIR-2218

    Drug: VIR-2218 VIR-2218 given by subcutaneous injection

    Drug: VIR-2218

  • Placebo comparator
    Placebo

    Drug: Placebo Saline given by subcutaneous injection

    Drug: Placebo

Interventions

  • VIR-2218 given by subcutaneous injection

  • DrugPlacebo

    Saline given by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)

    Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 are summarized by cohort. Incidence is defined as the number of participants with TEAEs in relation to the total number of participants in the cohort. TEAEs are defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.

    Time frame: up to 48 weeks

  2. Clinical Assessments Including But Not Limited to Laboratory Test Results

    Number of participants with graded hematology, coagulation, chemistry abnormalities, and clinically significant abnormalities in vital signs and ECGs

    Time frame: up to 48 weeks

Secondary outcomes

  1. PK: Maximum Plasma Concentration

    VIR-2218 and metabolite maximum plasma concentrations (ng/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Maximum plasma concentrations were calculated based on all above results for Day 1 and Day 29 (Week 4).

  2. PK: Time to Reach Maximum Plasma Concentration

    VIR-2218 and metabolite time to Cmax (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Time to Cmax were calculated based on all above results for Day 1 and Day 29 (Week 4).

  3. PK: Area Under the Plasma Concentration Versus Time Curve to Last Measurable Timepoint

    VIR-2218 and metabolite area under the curve from time 0 to last measurable time (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).

  4. PK: Area Under the Plasma Concentration Versus Time Curve to Infinity

    VIR-2218 and metabolite area under the curve from time 0 to infinity (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).

  5. PK: Percent of Area Extrapolated From AUC Last to Infinity

    VIR-2218 and metabolite percent of area extrapolated from AUC last to infinity (%) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Percent of area extrapolated from AUC last to infinity were calculated based on all above results for Day 1 and Day 29 (Week 4).

  6. PK: Apparent Terminal Elimination Half-life

    VIR-2218 and metabolite apparent terminal elimination half-life (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Apparent terminal elimination half-life were calculated based on all above results for Day 1 and Day 29 (Week 4).

  7. PK: Apparent Plasma Clearance

    VIR-2218 and metabolite apparent plasma clearance CL/F (mL/h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Apparent plasma clearance were calculated based on all above results for Day 1 and Day 29 (Week 4).

  8. PK: Apparent Volume of Distribution

    VIR-2218 and metabolite apparent volume of distribution Vz/F (mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

    Time frame: Apparent volume of distribution were calculated based on all above results for Day 1 and Day 29 (Week 4).

  9. Maximum Change of Serum HBsAg From Baseline

    Maximum change of serum HBsAg from Day 1 until 12 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)

    Time frame: up to 16 weeks

  10. Number of Participants With Serum HBsAg Loss

    Number of participants with serum HBsAg \< 0.05 IU/mL at two or more consecutive measurements

    Time frame: up to 48 weeks

  11. Number of Participants With Sustained Serum HBsAg Loss for at Least 6 Months

    Number of participants with sustained serum HBsAg \< 0.05 IU/mL at all visits for at least 6 months

    Time frame: up to 48 weeks

  12. Number of Participants With Anti-HBs Seroconversion at Any Timepoint

    Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements

    Time frame: up to 48 weeks

  13. For HBeAg-positive Subjects: Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint

    HBeAg loss is defined as quantitative HBeAg \< 0.14 IU/mL at two or more consecutive measurements. Anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements.

    Time frame: up to 48 weeks

07

Results

Posted Aug 26, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50mgPart 2: VIR-2218 100 mgPart 2: Placebo
Started443442
Dosed443442
Completed333432
Not completed110010
Withdrew: Withdrawal by subject110000
Withdrew: Lost to follow-up000010

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs)

Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 are summarized by cohort. Incidence is defined as the number of participants with TEAEs in relation to the total number of participants in the cohort. TEAEs are defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs)
ParticipantsPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Any TEAEs120211
Any TEAEs of CTCAE Grade 1010211
Any TEAEs of CTCAE Grade 2110000
Any TEAEs of CTCAE Grade 3 or above000000
Any drug related TEAEs000110
Any serious TEAEs000000
PrimaryClinical Assessments Including But Not Limited to Laboratory Test Results

Number of participants with graded hematology, coagulation, chemistry abnormalities, and clinically significant abnormalities in vital signs and ECGs

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
Clinical Assessments Including But Not Limited to Laboratory Test Results
ParticipantsPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Any post baseline laboratory abnormalities of CTCAE Grade 1442242
Any post baseline laboratory abnormalities of CTCAE Grade 2 or above000000
Any clinically significant vital signs000000
Any clinically significant ECGs000000
SecondaryPK: Maximum Plasma Concentration

VIR-2218 and metabolite maximum plasma concentrations (ng/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Maximum plasma concentrations were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · ng/mL
PK: Maximum Plasma Concentration
ng/mLPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 Cmax (Day 1)120 ± 40.5144 ± 100.565.8 ± 58.6260 ± 90.4
VIR-2218 Cmax (Day 29)125 ± 48.8198 ± 52.976.5 ± 35.7268 ± 43.0
AS(N-1)3'VIR-2218 Cmax (Day 1)10.2 ± NA31.4 ± NA—28.1 ± 171.1
AS(N-1)3'VIR-2218 Cmax (Day 29)16.3 ± NA23.6 ± 48.89.75 ± 1.119.3 ± 82.1
SecondaryPK: Time to Reach Maximum Plasma Concentration

VIR-2218 and metabolite time to Cmax (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Time to Cmax were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Median · hour
PK: Time to Reach Maximum Plasma Concentration
hourPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 Tmax (Day 1)4.99 (1.88 to 8.03)2.00 (0.967 to 8.08)4.02 (4.00 to 7.80)4.00 (4.00 to 7.58)
VIR-2218 Tmax (Day 29)7.76 (1.08 to 8.13)4.02 (2.00 to 7.85)2.50 (0.967 to 4.00)5.93 (1.00 to 8.02)
AS(N-1)3'VIR-2218 Tmax (Day 1)7.95 (3.98 to 8.05)4.98 (2.03 to 7.92)7.80 (7.80 to 7.80)5.79 (4.00 to 22.1)
AS(N-1)3'VIR-2218 Tmax (Day 29)7.76 (4.05 to 8.13)5.93 (2.00 to 8.03)4.00 (4.00 to 4.00)5.93 (4.00 to 8.02)
SecondaryPK: Area Under the Plasma Concentration Versus Time Curve to Last Measurable Timepoint

VIR-2218 and metabolite area under the curve from time 0 to last measurable time (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Plasma Concentration Versus Time Curve to Last Measurable Timepoint
ng*h/mLPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 AUClast (Day 1)1080 ± 25.31400 ± 115.6626 ± 31.13190 ± 42.3
VIR-2218 AUClast (Day 29)854 ± 34.22390 ± 26.6580 ± 56.93140 ± 15.8
AS(N-1)3'VIR-2218 AUClast (Day 1)58.7 ± 28.9159 ± 30.567.6 ± 2.1180 ± 63.4
AS(N-1)3'VIR-2218 AUClast (Day 29)50.2 ± 52.5140 ± 81.263.1 ± 6.1155 ± 39.8
SecondaryPK: Area Under the Plasma Concentration Versus Time Curve to Infinity

VIR-2218 and metabolite area under the curve from time 0 to infinity (ng\*h/mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Area under the curve were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Plasma Concentration Versus Time Curve to Infinity
ng*h/mLPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 AUCinf (Day 1)—2820 ± 16.7——
VIR-2218 AUCinf (Day 29)—2570 ± NA1210 ± NA3530 ± NA
SecondaryPK: Percent of Area Extrapolated From AUC Last to Infinity

VIR-2218 and metabolite percent of area extrapolated from AUC last to infinity (%) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Percent of area extrapolated from AUC last to infinity were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · % of AUCinf
PK: Percent of Area Extrapolated From AUC Last to Infinity
% of AUCinfPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 %AUCextrap (Day 1)—2.69 ± 5.1——
VIR-2218 %AUCextrap (Day 29)46.2 ± NA13.8 ± NA23.9 ± 263.45.88 ± NA
AS(N-1)3'VIR-2218 %AUCextrap (Day 29)—49.2 ± NA——
SecondaryPK: Apparent Terminal Elimination Half-life

VIR-2218 and metabolite apparent terminal elimination half-life (h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Apparent terminal elimination half-life were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Median · hour
PK: Apparent Terminal Elimination Half-life
hourPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 t1/2 (Day 1)—4.16 (4.10 to 4.22)——
VIR-2218 t1/2 (Day 29)—7.66 (7.66 to 7.66)6.53 (6.53 to 6.53)5.49 (5.49 to 5.49)
SecondaryPK: Apparent Plasma Clearance

VIR-2218 and metabolite apparent plasma clearance CL/F (mL/h) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Apparent plasma clearance were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · mL/h
PK: Apparent Plasma Clearance
mL/hPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 CL/F (Day 1)—35400 ± 16.7——
VIR-2218 CL/F (Day 29)—39000 ± NA41300 ± NA28300 ± NA
SecondaryPK: Apparent Volume of Distribution

VIR-2218 and metabolite apparent volume of distribution Vz/F (mL) VIR-2218 and metabolite concentrations were tested at predose on Day 1 and 1h, 2h, 4h, 8h, and 24h postdose, Week 1, predose on Week 4 and 1h, 2h, 4h, 8h, and 24h postdose, Week 5, Week 8, Week 16, and Week 24.

Time frame:
Apparent volume of distribution were calculated based on all above results for Day 1 and Day 29 (Week 4).
Reported as:
Geometric mean · mL
PK: Apparent Volume of Distribution
mLPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mg
VIR-2218 Vz/F (Day 1)—213000 ± 18.6——
VIR-2218 Vz/F (Day 29)—431000 ± NA389000 ± NA224000 ± NA
SecondaryMaximum Change of Serum HBsAg From Baseline

Maximum change of serum HBsAg from Day 1 until 12 weeks post last dose (negative values mean reductions from baseline, positive values mean increased from baseline)

Time frame:
up to 16 weeks
Reported as:
Mean · log10 IU/mL
Maximum Change of Serum HBsAg From Baseline
log10 IU/mLPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Maximum Change of Serum HBsAg From Baseline-1.064 ± 0.1047-1.346 ± 0.5169-0.049 ± 0.0158-0.793 ± 0.1017-1.268 ± 0.1693-0.120 ± 0.0826
SecondaryNumber of Participants With Serum HBsAg Loss

Number of participants with serum HBsAg \< 0.05 IU/mL at two or more consecutive measurements

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serum HBsAg Loss
ParticipantsPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Number of Participants With Serum HBsAg Loss000000
SecondaryNumber of Participants With Sustained Serum HBsAg Loss for at Least 6 Months

Number of participants with sustained serum HBsAg \< 0.05 IU/mL at all visits for at least 6 months

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With Sustained Serum HBsAg Loss for at Least 6 Months
ParticipantsPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Number of Participants With Sustained Serum HBsAg Loss for at Least 6 Months000000
SecondaryNumber of Participants With Anti-HBs Seroconversion at Any Timepoint

Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-HBs Seroconversion at Any Timepoint
ParticipantsPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
Number of Participants With Anti-HBs Seroconversion at Any Timepoint000010
SecondaryFor HBeAg-positive Subjects: Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint

HBeAg loss is defined as quantitative HBeAg \< 0.14 IU/mL at two or more consecutive measurements. Anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements.

Time frame:
up to 48 weeks
Reported as:
Count of participants · Participants
For HBeAg-positive Subjects: Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint
ParticipantsPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
HBeAg loss000
Anti-HBe seroconversion000

Adverse events

Collected over Up to 48 weeks after the first dose of VIR-2218 or placebo. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: VIR-2218 50 mg0/4 (0%)0/4 (0%)1/4 (25%)
Part 1: VIR-2218 100 mg 100 mg0/4 (0%)0/4 (0%)2/4 (50%)
Part 1: Placebo0/3 (0%)0/3 (0%)0/3 (0%)
Part 2: VIR-2218 50 mg0/4 (0%)0/4 (0%)2/4 (50%)
Part 2: VIR-2218 100 mg0/4 (0%)0/4 (0%)1/4 (25%)
Part 2: Placebo0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventPart 1: VIR-2218 50 mgPart 1: VIR-2218 100 mg 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: Placebo
AnaemiaBlood and lymphatic system disorders0/40/40/30/40/41/2
DiarrhoeaGastrointestinal disorders0/40/40/31/40/40/2
Epigastric discomfortGastrointestinal disorders0/40/40/31/40/40/2
ToothacheGastrointestinal disorders1/40/40/30/40/40/2
Decreased appetiteMetabolism and nutrition disorders0/40/40/30/41/40/2
HyperuricaemiaMetabolism and nutrition disorders0/40/40/31/40/40/2
FatigueGeneral disorders0/40/40/30/41/40/2
Upper respiratory tract infectionInfections and infestations0/41/40/30/40/40/2
Animal biteInjury, poisoning and procedural complications0/41/40/30/40/40/2
SomnolenceNervous system disorders0/40/40/31/40/40/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: PlaceboTotal
Mean48.5 ± 9.6836.5 ± 9.2631.0 ± 5.2041.8 ± 4.2739.5 ± 10.6638.0 ± 11.3139.7 ± 9.26
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: PlaceboTotal
Female0001113
Male44333118
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: PlaceboTotal
American Indian or Alaska Native0000000
Asian44344221
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White0000000
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Part 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: PlaceboTotal
China44344221
Baseline log10 hepatitis B surface antigen
Baseline log10 hepatitis B surface antigen(log10 IU/mL)Part 1: VIR-2218 50 mgPart 1: VIR-2218 100 mgPart 1: PlaceboPart 2: VIR-2218 50 mgPart 2: VIR-2218 100 mgPart 2: PlaceboTotal
Mean2.815 ± 0.48653.278 ± 0.79102.948 ± 0.48223.598 ± 0.54793.243 ± 0.48483.722 ± 0.07293.239 ± 0.5756
08

Study locations

2 sites
  • Investigative Site
    Beijing, Beijing, China
  • Investigative Site
    Changchun, Jilin, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2021, 13 months.

Results were first posted in Aug 2024, 2 years 10 months after primary completion. A results delay was requested in Jul 2022.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 13 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 11, 2020
StartActual
Aug 18, 2020
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Results delay requested
Jul 26, 2022
Results first posted
Aug 26, 2024
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04507269
Lead sponsor
Brii Biosciences Limited
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Aug 18, 2020
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Results posted
Aug 26, 2024
Last update
Aug 26, 2024

Study contacts

Xiaofei Chen
study director · Brii Biosciences Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elebsiran

Start the discussion